Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

S and AML Patients

CHICAGO, Ill. June 2, 2007 - Pharmion Corporation (NASDAQ:PHRM) and MethylGene Inc. (TSX:MYG) today announced preliminary Phase II and Phase I/II data for their lead oncology product candidate, MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor which showed significant anti-tumor activity in patients with Hodgkin's lymphoma, Myelodysplastic Syndromes and acute myelogenous leukemia. The data were presented Saturday at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Hodgkin's Lymphoma (Trial 010)

Data presented show an objective complete and partial response rate of 40 percent and a disease control rate of 45 percent in a population of patients that had relapsed disease or were refractory (unresponsive) to all previous treatments, including, in many cases, bone marrow transplantation. Overall, 75 percent of patients experienced a reduction in tumor size, with 60 percent experiencing a tumor reduction of greater than 30 percent.

"It is striking that single-agent therapy with MGCD0103 achieved such impressive objective clinical responses in this population," said Anas Younes, M.D., principal investigator and Professor of Medicine and Director, Clinical Investigation and Translational Research in the Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center. "No approved therapies exist for patients suffering from Hodgkin's lymphoma that has progressed following transplantation. With a novel mechanism of action and an oral route of administration, MGCD0103 would be a welcome and desirable addition to the Hodgkin's lymphoma armamentarium."

The data were presented as part of a clinical symposium titled, "Breaking the Silence of the Genome: HDAC Inhibitors," which focused on the progress and potential of this emerging therapeutic category. The HDACs are enzymes that mediate histone deacetylation, an epigenetic form of gene regulation that may silence tumor suppres
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ... reported financial results for the second quarter and three and ... are expressed in Canadian dollars and in accordance with International ... ESSA recorded a net loss of $5.9 million ... 31, 2015 (Q2-2015), compared to a net loss of $0.4 ...
(Date:5/28/2015)... 2015  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... H. Mackaness is scheduled to present at the LD ... PT in Los Angeles . ... on the Event Calendar of the Investors section of IRIDEX,s ... will be available shortly after the conclusion of the presentation ...
(Date:5/28/2015)... 2015 Research and ... of the  "North America Ultrasound Devices Market ... 2019)"  report to their offering.  ... a type of imaging. It uses high-frequency ... and structures inside the body. Health care ...
Breaking Medicine Technology:Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2
... Prolong Pharmaceuticals today announced that industry veteran Glenn Kazo has ... in various capacities with Prolong since 2007. He succeeds Prolong ... "I have known Glenn for more than thirty years," ... Mr. Kazo. "I feel he is one of the greatest ...
... 28 Tigris Pharmaceuticals, Inc., a ... it has completed a private placement of Series ... of approximately $6.5 million.  The financing, which was ... investors Wexford Spectrum Investors, LLC, and Sonostar Capital ...
Cached Medicine Technology:Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President 2Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 2Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 3
(Date:5/29/2015)... 2015 Dr. Rodger Murphree, author ... Syndrome is now offering free weekly call in ... natural ways to reduce symptoms associated with fibromyalgia ... and brain fog. , To find out ... Fibromyalgia call in teleconferences simply go to ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 This ... current state of the Naproxen industry.The report provides ... classifications, applications and industry chain structure. The ... international markets including development trends, competitive landscape analysis, ... are discussed as well as manufacturing processes and ...
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... researchers use percent of body fat data to assess obesity ... obesity rates between African-American //and white women, for example, is ... a much higher risk of obesity than African-American men. ... of body fat is a more accurate measure of fatness ...
... China today agreed to reconduct lab tests to find out ... in Beijing as early as 2003, after eight of its ... ,The Chinese Ministry of Health said it was conducting new ... , ,"In accordance with World Health Organisation and China's ...
... These findings raise the possibility that heart infection could ... that affect humans and livestock //, and that these ... paper is being published on Friday, July 7 in ... ,Prion diseases-also known as transmissible spongiform encephalopathies because ...
... to a study which was published in the International Journal ... against billiary tract cancer //and reduced the risk of developing ... but are fatal. Bile stones on the other hand are ... that about 10% of the patients who had undergone treatment ...
... at Pahihari village near here has caused a scare among ... ,The local Primary Health Centre (PHC) here today constituted a ... to the diseases, they said., ,At least one member ... from either malaria or jaundice, the officials said., ,Bantaram, ...
... to bring ethnic Singapore foods to the U.S., China, ... new frozen food technology.// ,Local food manufacturer, Terry Tan ... ethnic flavors of Singapore available worldwide. ,Extending ... major challenges towards making Terry Tan’s plans a reality. ...
Cached Medicine News:Health News:Prion Disease Agent Causes Heart Damage 2Health News:Prion Disease Agent Causes Heart Damage 3Health News:Prion Disease Agent Causes Heart Damage 4
... a long-pulsed Nd:YAG laser system with a wavelength ... treat deep-lying, superficial as well as red and ... epilation in patients with darker skin types (1 ... as for general improvement of skin texture. The ...
... brachytherapy source consists of a welded titanium ... onto four resin beads. The capsule ... which serve as x-ray markers to identify ... sources are supplied non-sterile when shipped and ...
... SINON is a Q-switched ruby ... of 694 nm. High Performance ... - This combination of high ... in Q-switched mode effectively destroys ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
Medicine Products: